期刊文献+

阿克拉霉素对HeLa细胞染色体形成及细胞凋亡的影响 被引量:1

THE EFFECTS OF ACLARUBICIN ON THE CHROMOSOME FORMATION OF HELA CELL AND APOPTOSIS
下载PDF
导出
摘要 目的 :探讨阿克拉霉素对HeLa细胞染色体形成的影响机制及与细胞凋亡的关系。 方法 :MTT方法测定阿克拉霉素对HeLa细胞的IC50 值。不同浓度阿克拉霉素作用于HeLa细胞24h后 ,制备染色体 ,Giemsa染色 ,观察 ;应用吖啶橙和嗅乙啶双荧光染色及DNA凝胶电泳检测细胞凋亡 ;Western_blot分析半胱氨酸蛋白酶_3(caspase_3)含量变化。 结果 :阿克拉霉素对HeLa细胞的IC50 值为6.83μg/ml。染色体分析表明 ,阿克拉霉素作用于HeLa细胞一定时间后 ,染色体不规则凝集 ,正常M期染色体形成受阻。细胞凋亡检测可见10μg/ml药物组与0.1μg/ml组及对照组相比 ,差异显著。Western_blot分析表明 ,10μg/ml药物组caspase_3表达比0.1μg/ml组和对照组显著增加。 结论 :阿克拉霉素能够阻止HeLa细胞染色体形成与分离 ,导致细胞G2/M期阻滞 ,诱导细胞凋亡。 Purpose: To investigate the mechanism of chromosome formation of HeLa cell line induced by aclarubicin and the relationship of aclarubicin to apoptosis. Methods: MTT assay was used to detect the half_inhibition concentration (IC 50) of a clarubicin on HeLa cell line, then aclarubicin with different concentrations was chosen to treat HeLa cells for 24 hours, and the nuclei and chromosomes were stained with Giemsastain. Apoptosis of HeLa cell was detected with acridine orange and ethidium bromide(AO / EB) double fluorescence stain and agarose g el electrophoresis. Caspase_3 was assessed with western blot met hod. Results: After HeLa cells were treated with aclarubicin, the IC 50 was 6.83 μg / ml. The normal chromosome formation w as blocked and chromatin condensed disorderly. Apoptosis and DNA fragments were apparent in the 10 μg / ml group. The caspa se_3 content in the 10 μg / ml group also showed a marked increase compared with the control and the 0.1 μg / ml group . Conclusion: Aclarubicin can inhibit the normal chromatin conde nsation and induce the cells G 2 / M arrest, and causes apopto sis. Caspase_3 may play an important role in apoptosis of He La cells induced by aclarubicin.
出处 《癌变.畸变.突变》 CAS CSCD 2003年第2期84-87,共4页 Carcinogenesis,Teratogenesis & Mutagenesis
关键词 阿克拉霉素 染色质凝集 细胞凋亡 半胱氨酸蛋白酶-3 aclarubicin (ACR) chromatin condensation apoptosis caspase_3
  • 相关文献

参考文献13

  • 1阎蕴力,郑力芬,张英辉,王美华,刘军须.威猛(VM-26)诱导Hela细胞G_2期停滞及染色体损伤分析[J].癌变.畸变.突变,1998,10(3):155-159. 被引量:2
  • 2阎蕴力,郑力芬,王美华,杨天祝,马常生.威猛(Vm-26)对Hela细胞染色体形成的影响[J].癌变.畸变.突变,1996,8(3):161-164. 被引量:3
  • 3Sinha BK. Topoisomerase inhibitors-a review of their therapeutic potential in cancer[J]. Drugs, 1995,49(1): 11-19.
  • 4Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity othuman topoisomerase Ⅱ α by blocking DNA cleavage[J]. J Biol Chem, 1998, 273(28) : 17 643 - 17 650.
  • 5Nagata T, Higashigawa M, Shimono Y, et al. Aclarubicine inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 mutine leukemia cens[J]. J Exp Clin Cancer Res,1998, 17(4) : 435 - 443.
  • 6Grue P, Grabert A, Sehested M, et al. Essential mitotic function of DNA topoisomerase Ⅱ α are not adopted by topoisomerase Ⅱ β in human H69 cells[J]. J Biol Chem, 1998, 273(50) : 33 660 -33 666.
  • 7Warburton PE, Eamshaw WC. Untangling the role of DNA topoisomerase Ⅱ in mitotic chromosome structure and function[J]. Bio Essays, 1995, 19(2) : 97 - 99.
  • 8Charron M, Hancock R. DNA topoisomerase Ⅱ is required for formation of mitotic chromosomes in Chinese hamster ovary cells:Studies using the inhibitor 4'-Demethylepipodophyllotoxin 9-(4,60-Thenylidem-β-d-glucopyranoside)Biochem,1990,29(41): 531- 9 537.
  • 9Chen M, Beck W. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase Ⅱ inhibitors Merbarone and VM-26[J]. Cancer Res, 1995, 55(7) : 1 509- 1 516.
  • 10Gorbsky GJ. Cell cycle progression and chromosome segregation in mammalian cell cultured in the presence of the tpoisomerase Ⅱ inhibitors ICRF-187[( + ) - 1, 2- his(3, 5-dioxopiperazinyl-l-yl)propane; ADR-529] and ICRF-159 (Razoxane)[J]. Career Res,1994, 54(4) : 1 042 - 1 048.

二级参考文献4

  • 1阎蕴力,癌变.畸变.突变,1996年,8卷,161页
  • 2Chen M,Cancer Res,1995年,55卷,1509页
  • 3章静波,细胞生物学实用方法与技术,1995年,53页
  • 4Cheng X,Cancer Res,1993年,53卷,5592页

共引文献2

同被引文献20

  • 1LiangFeng(梁峰) WeiJun(魏俊) LiZhaoyang(李朝阳) WuChengtai(吴成泰) ZhengCongyi(郑从义) SunMengxiang(孙蒙祥).高等学校化学学报,2004,25:470-473.
  • 2Indrani B. , Frederick F. B. , Bimal K. B.. J. Med. Chem. [J], 2003, 46:12-15
  • 3Adam W. , David C. K. , Brian O. P. et al.. Inorganic Chemistry Communication[J], 2003, 6:996-1000
  • 4Lepecq J. B. , Paolett C.. J. Mol. Biol. [J], 1967, 27:87-90
  • 5Butor J. L. , Wimmer S. , Wimmer F. et al.. Chemico-Biological Interactions[J], 1997, 104:165-170
  • 6Rosenberg B.. Cancer[J], 1985, 55:2303-2310
  • 7Bogdanov A. A. J. , Martin C. , Bogdanova A. V. et al.. Bioconjugate Chem. [J] , 1996, 7:144-149
  • 8Meyn R. E. , Stephens L. C. , Hunter N. R. et al.. Int. J. Cancer[J] , 1995, 60:725-729
  • 9Francisco J. R. , Oldrich V. , Adoracio'n G. Q. et al.. J. Med. Chem. [J], 2006, 49:2640-2651
  • 10Jaroslav M. , Marie V. , Viktor B. et al.. Biochemical and Biophysical Research Communications[J], 2005, 332:1034-1041

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部